TargImmune Therapeutics
Privately held Swiss biotechnology company (Basel) developing a targeted nucleic acid delivery platform that uses synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics systemically to solid tumours. The platform aims to induce apoptosis and modulate immune responses in cancer cells and is being advanced through preclinical GLP/toxicology studies toward IND/CTA filing and first-in-human studies.
Industries
Nr. of Employees
small (1-50)
TargImmune Therapeutics
Patents
Systems and methods for automatically generating a data center network mapping for automated alarm consolidation
US-11743104-B2
View Details
Systems and methods for automatically generating a data center network mapping for automated alarm consolidation
US-11743104-B2
View DetailsProducts
TAR001
Lead targeted nucleic acid therapeutic candidate that targets epidermal growth factor receptor (EGFR) to deliver synthetic dsRNA to tumours overexpressing the receptor; advanced toward IND/CTA and first-in-human studies.
TAR002
Second platform-based nucleic acid therapeutic candidate in preclinical development (portfolio compound).
TAIMs
Targeted apoptosis and immune modulators utilizing synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics directly on target.
TAR003
Pipeline candidate molecule under the TAIM development programme focusing on a key receptor target.
TAR001
Lead targeted nucleic acid therapeutic candidate that targets epidermal growth factor receptor (EGFR) to deliver synthetic dsRNA to tumours overexpressing the receptor; advanced toward IND/CTA and first-in-human studies.
TAR002
Second platform-based nucleic acid therapeutic candidate in preclinical development (portfolio compound).
TAIMs
Targeted apoptosis and immune modulators utilizing synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics directly on target.
TAR003
Pipeline candidate molecule under the TAIM development programme focusing on a key receptor target.
Expertise Areas
- Targeted nucleic acid delivery
- Oncology therapeutics for solid tumours
- Preclinical development and GLP toxicology
- IND/CTA regulatory readiness
Key Technologies
- Targeted nanoparticle delivery
- Synthetic double-stranded RNA therapeutics (Poly-IC)
- Receptor-specific targeting moieties (e.g., EGFR-directed delivery)
- Systemic nucleic acid delivery to primary and metastatic tumours
News & Updates
Announcement of completion of GLP toxicology studies and appointment of a Head of Technical Development to support progression toward clinical studies and CMC/scale-up.
Appointment of a Chief Medical Officer to support clinical development and preparation for IND/CTA and human studies.
Completed a CHF 17.7 million financing round and announced appointment of a new Chief Executive Officer to lead clinical advancement.
Announcement of a full-time Chief Financial Officer to guide financial strategy and funding options.
Profile and coverage describing the company's approach to harnessing antiviral defence mechanisms via targeted nucleic acid therapeutics.
Completed GLP-compliant toxicology studies supporting a path to human studies.
Announcement of completion of GLP toxicology studies and appointment of a Head of Technical Development to support progression toward clinical studies and CMC/scale-up.
Appointment of a Chief Medical Officer to support clinical development and preparation for IND/CTA and human studies.
Completed a CHF 17.7 million financing round and announced appointment of a new Chief Executive Officer to lead clinical advancement.
Announcement of a full-time Chief Financial Officer to guide financial strategy and funding options.
Profile and coverage describing the company's approach to harnessing antiviral defence mechanisms via targeted nucleic acid therapeutics.
Completed GLP-compliant toxicology studies supporting a path to human studies.